Litcius/Paper detail

LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Marina Chiara Garassino, Willemijn S.M.E. Theelen, Robert M. Jotte, Janessa Laskin, Filippo de Marinis, Carlos Aguado, Firas Badin, Izabela Chmielewska, Maximilian J. Hochmair, Shun Lu, Ernest Nadal, Gyula Ostoros, Enriqueta Felip, Alexander I. Spira, Conor M. Lane, Jinghua He, Richard C. Chao, Pasi A. Jänne

2023Annals of Oncology49 citationsDOIOpen Access PDF

Topics & Concepts

MedicineDiscontinuationPembrolizumabAdverse effectInternal medicineLung cancerNauseaOncologyCancerImmunotherapyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies
LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation | Litcius